Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of BAIBA (beta-aminoisobutyric acid) in preparation of anti-DM (diabetes mellitus) drugs

An aminoisobutyric acid, anti-diabetic technology, applied in the field of medicine, can solve problems such as the effect of β-aminoisobutyric acid that has not been reported, and achieve the effect of broadening the selection field

Inactive Publication Date: 2016-01-20
NANJING MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

β-aminoisobutyric acid is a metabolite regulated by PGC-1a protein, and there is no report on the role of β-aminoisobutyric acid in the preparation of antidiabetic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of BAIBA (beta-aminoisobutyric acid) in preparation of anti-DM (diabetes mellitus) drugs
  • Application of BAIBA (beta-aminoisobutyric acid) in preparation of anti-DM (diabetes mellitus) drugs
  • Application of BAIBA (beta-aminoisobutyric acid) in preparation of anti-DM (diabetes mellitus) drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] The making of embodiment 1 diabetes model

[0016] Eight-week-old C57BL / 6J mice were randomly divided into three groups:

[0017] (1) Normal mouse group (Ctrl): normal control group, given normal diet (non-high-fat diet);

[0018] (2) Diabetes group (STZ / HFD): Diabetes induced by streptozotocin (STZ) combined with high-fat diet (HFD);

[0019] (3) Diabetes-β-aminoisobutyric acid group (STZ / HFD-BAIBA): Diabetes was induced by streptozotocin (STZ) combined with high-fat diet (HFD), and β-aminoisobutyric acid was administered after drinking water for 8 weeks. Dosing for 4 weeks.

[0020] Diabetes model making method: The diabetes model is induced by combined application of small doses of STZ and high-fat diet, which is a recognized animal model of type II diabetes. The specific method is: a small dose of STZ (120 mg / kg) is intraperitoneally injected once after fasting for 4 hours, and the normal control group is injected with vehicle as a control. After 3 weeks, the di...

Embodiment 2

[0022] Embodiment 2 Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT)

[0023] Glucose tolerance test (glucosetolerancetest, GTT): After the mice were fasted overnight, glucose (2.0 g / kg) was injected intraperitoneally, and the blood glucose was measured before and 15, 30, 60 and 120 minutes after the injection, respectively.

[0024] Insulin tolerance test (insulintolerance test, ITT): mice were fasted overnight, and insulin (0.75 units / kg) was injected intraperitoneally, and blood glucose was measured before and 15, 30, 60 and 120 minutes after injection, respectively.

Embodiment 3

[0025] Example 3 Expression of liver gluconeogenesis key enzymes

[0026] Phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6 phosphatase (G6Pase) are the key enzymes of gluconeogenesis. The protein expressions of these two key enzymes of gluconeogenesis were detected by Western blot method.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of BAIBA (beta-aminoisobutyric acid) in preparation of anti-DM (diabetes mellitus) drugs. A novel treatment means is provided for preparation of the anti-DM drugs, BAIBA is applied to development of DM related drugs, and accordingly, the better DM treatment drugs are prepared. After BAIBA is delivered to a mouse with STZ / HFD (streptozocin / high fat diet) induced DM, the fasting blood-glucose level is remarkably reduced, insulin sensitivity is remarkably improved, and further, with the adoption of BAIBA, gluconeogenesis is reduced and an insulin molecular signal pathway is improved. Therefore, BAIBA can remarkably improve insulin resistance and glycometabolic disorder caused by DM, is an effective target site for DM treatment and can be taken as the novel anti-DM drug for development, and one novel pathway and means is provided for DM detection and treatment.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of β-aminoisobutyric acid in the preparation of antidiabetic drugs. Background technique [0002] Diabetes Mellitus (DM) is a series of systemic metabolic disorders caused by relative or absolute insulin deficiency, or decreased sensitivity of target cells to insulin. According to the cause of the disease and the distribution in different populations, diabetes is often divided into type I diabetes and type II diabetes clinically. Diabetes is a common clinical endocrine and metabolic disease, and another chronic disease that seriously endangers human health after cardiovascular and cerebrovascular diseases and tumors. At present, the incidence of diabetes in the world is on the rise, among which type II diabetes is the majority. In my country, type II diabetes accounts for about 95% of diabetic patients, and there is a tendency to expand and rejuvenate. [0003] Type II d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61P3/10
Inventor 朱国庆施长香熊晓青高兴亚王觉进
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com